Noradrenergic modulation of γ-aminobutyric acid outflow from the human cerebral cortex

doi:10.1016/0006-8993(93)90487-8

Brain Research

Volume 629, Issue 1, 26 November 1993, Pages 103-108

https://doi.org/10.1016/0006-8993(93)90487-8 Get rights and content

Abstract

The noradrenergic modulation of endogenous γ-aminobutyric acid (GABA) outflow from slices and synaptosomes prepared from human cerebral cortex biopsies has been studied. GABA outflow was responsive to depolarizing stimuli such as ouabain and high potassium. Basal GABA outflow in slices, but not in synaptosomes, appeared to be largely dependent upon neuronal activity, being prevented by tetrodotoxin (TTX). 10 mM K⁺-evoked outflow in synaptosomes also proved to be TTX sensitive. Norepinephrine (NE) concentration dependently increased basal GABA outflow both in slices and synaptosomes. This effect wasα₁-adrenoreceptor-mediated because it was prevented by a selective antagonist of theα₁-adrenoreceptor class (prazosin) but not by theα₁ antagonist idazoxan. However, andα₁-mediated inhibitory modulation was also present in the preparations used, since (1) in slices, NE significantly inhibited GABA outflow in the presence of prazosin; (2) in synaptosomes, NE significantly inhibited 10 mM K⁺-evoked outflow in the presence of prazosin. Both of these effects were prevented by idazoxan. No β-adrenoreceptor modulation could be demonstrated. A comparison between species was also conducted. The response to ouabain and to TTX proved similar in human, rat and guinea-pig cerebral cortex. In the most simple tissue preparation used (synaptosomes), a close similarity between the three species could be observed. In all species, NE stimulated basal GABA outflow, an effect prevented by prazosin. This suggests a predominantα₁-adrenoreceptor-mediated stimulatory effect. In a more complex preparation (slices), differences between species could be demonstrated. First, in absolute values basal GABA outflow was higher in the rat compared to the human and the guinea-pig cortex. Second, although NE stimulated GABA outflow viaα₁-adrenoreceptors in all species, it wa more potent in the rat. Third, in the presence of prazosin NE significantly inhibited basal GABA outflow in the human cortex, but not in the other species. This suggests that the representation of functionalα₂-adrenoreceptors (on the cell bodies of GABA neurones and /or other connected neuronal populations) is greater in the human when compared to the rat and the guinea-pig cerebral cortex.

Reference (21)

BeaniL. et al.
Noradrenalin inhibition of acetylcholine release from guinea-pig brain
Eur. J. Pharmacol.
(1978)
DoddP. et al.
Synaptosomes prepared from fresh human cerebral cortex; morphology, respiration and release of transmitter amino acids
Brain Res.
(1981)
HarrisonJ.K. et al.
Molecular characterization ofα₁-andα₂-adrenoreceptors
Trends Pharmacol. Sci.
(1991)
HaugstadT.S. et al.
Calcium dependent release of γ-aminobutyric acid (GABA) from human cerebral cortex
Neurosci. Lett.
(1992)
Javoy-AgidF. et al.
Distribution of monoaminergic, cholinergic and GABAergic markers in the human cerebral cortex
Neuroscience
(1989)
LowryO.H. et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951)
McCormickD.A.
Refinements in the in vitro slices technique and human neuropharmacology
Trends Pharmacol. Sci.
(1990)
PalaciosJ.M. et al.
Alpha-1-adrenoceptors in mammalian brain: similar pharmacology but different distribution in rodents and primates
Brain Res.
(1987)
PalaciosJ.M. et al.
Mapping receptors in the human brain
Trends Neurosci.
(1986)
SmithC.C.T. et al.
The evoked release of endogenous amino acids from tissue prisms of human neocortex
Brain Res.
(1983)

There are more references available in the full text version of this article.

Cited by (28)

Mechanisms underlying anticonvulsant and proconvulsant actions of norepinephrine
2018, Neuropharmacology
Citation Excerpt :
NE effect on neuronal excitability may be directly via a change in intrinsic excitability by modulation of ion channels conductance (Xiao et al., 2009; Pape and McCormick, 1989; Hille, 1994), or indirectly through synaptically-mediated excitability, commonly GABAergic and glutamatergic transmission. Previous studies have showed a bidirectional interaction between the noradrenergic and GABAergic systems; NE facilitates the presynaptic release of GABA (Pittaluga and Raiteri, 1987; Ferraro et al., 1993), and GABA induces NE release from noradrenergic axon terminals (Bonanno and Raiteri, 1987; Fassio et al., 1999) by activating GABAA receptors or GABA transporters on noradrenergic terminals (Fassio et al., 1999). Downregulation of both adrenergic receptors and GABAA receptors (Suzdak and Gianutsos, 1985; Dennis et al., 1994; Sanacora et al., 2000) following chronic treatment with NE-boosting antidepressants may be, at least in part, due to this interaction.
Norepinephrine (NE) has been shown to exert a potent suppressant effect on seizure development. On the other hand, several lines of evidence have shown that increased NE level is proconvulsant under certain conditions. These data suggest that variations in NE levels could affect modulatory action of noradrenergic system on seizures. Less, however, is known about the mechanisms by which adrenergic pathways protect against seizures or promote seizures. Knowing the mechanisms involved in anti- or proconvulsive effects of NE may help to the development of new therapeutic candidates for patients with refractory epilepsy. Here, we present some possible mechanisms involved in actions of NE on seizures.
Analgesic properties of the novel compound M43068 in rat models of acute and neuropathic pain
2005, European Journal of Pharmacology
We investigated the effects of 2-(4-hydroxybenzoyl)amino-2-methylpropionic acid (M43068), a novel analgesic agent, in rat models of acute and neuropathic pain. Oral M43068 (10–100 mg/kg) suppressed only the late phase of formalin-induced nociceptive behaviors. In the neuropathic pain model, oral M43068 (10–100 mg/kg) suppressed mechanical allodynia in the nerve-injured paw without affecting normal thresholds. On the other hand, i.v. M43068 (30 mg/kg) mainly suppressed the Aβ-fiber-mediated response with the Neurometer. I.c.v. pretreatment with the α₁-adrenoceptor antagonist, prazosin, or i.p. pretreatment with the γ-aminobutyric acid (GABA)_B receptor antagonist, saclofen, abolished the M43068-induced antinociception. However, oral M43068 (30–300 mg/kg) had no influence on blood pressure and motor function, unlike the α₁-adrenoceptor and the GABA_B receptor agonists. These data indicate that M43068 shows antinociceptive and anti-allodynic effects with reduced risks of side effects. It is suggested that the descending noradrenergic system is involved in the analgesic effects of M43068.
Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways
2005, Cellular Signalling
Antidepressants are commonly used in the treatment of anxiety and depression, medical conditions that affect ∼17–20% of the population. The clinical effects of antidepressants take several weeks to manifest, suggesting that these drugs induce adaptive changes in brain structures affected by anxiety and depression. In order to develop shorter-acting and more effective drugs for the treatment of anxiety and depression, it is important to understand how antidepressants bring about their beneficial effects. Recent reports suggest that antidepressants can induce neurogenesis in the adult brain, although the mechanisms involved are not clearly understood. In this review, we describe the different neurotransmitter systems that are affected by anxiety and depression and how they are modulated by antidepressant treatment with a focus on signaling molecules and pathways that are activated during neurotransmitter receptor induced neurogenesis.
Neuronal nicotinic receptors in synaptic functions in humans and rats: Physiological and clinical relevance
2000, Behavioural Brain Research
The present report describes the participation of nicotinic receptors (nAChRs) in controlling the excitability of local neuronal circuitries in the rat hippocampus and in the human cerebral cortex. The patch-clamp technique was used to record responses triggered by the non-selective agonist ACh and the α7-nAChR-selective agonist choline in interneurons of human cerebral cortical and rat hippocampal slices. Evidence is provided that functional α7- and α4β2-like nAChRs are present on somatodendritic and/or preterminal/terminal regions of interneurons in the CA1 field of the rat hippocampus and in the human cerebral cortex and that activation of the different nAChR subtypes present in the preterminal/terminal areas of the interneurons triggers the tetrodotoxin-sensitive release of GABA. Modulation by nAChRs of GABAergic transmission, which can result either in inhibition or disinhibition of pyramidal neurons, depends both on the receptor subtype present in the interneurons and on the agonist acting upon these receptors. Not only do α7 nAChRs desensitize faster than α4β2 nAChRs, but also α7 nAChR desensitization induced by ACh lasts longer than that induced by choline. These mechanisms, which appear to be retained across species, might explain the involvement of nAChRs in cognitive functions and in such neurological disorders as Alzheimer’s disease and schizophrenia.
Effect of noradrenergic inputs on the cardiovascular depressor responses to stimulation of central nucleus of the amygdala
1999, Brain Research
Experiments were done in chloralose anesthetized, paralyzed and artificially ventilated male Wistar rats to investigate the effects of microinjections of either norepinephrine (NE) or tyramine into the central nucleus of the amygdala (ACe) on the arterial pressure (AP) and heart rate (HR) responses elicited by glutamate (Glu) stimulation of the ACe. Microinjections of Glu into the ACe elicited decreases in mean AP (−23±3 mmHg) and HR (−11±3 bpm). Microinjections of NE or tyramine into these sites did not elicit cardiovascular responses. However, Glu into the ACe in the presence of NE or tyramine elicited depressor or bradycardic response that were significantly smaller (70–100%) in magnitude than to Glu alone. These data suggest that noradrenergic mechanisms in the ACe alter the excitability of ACe neurons involved in mediating changes in systemic AP and HR.
Inhibition of spontaneous inhibitory postsynaptic currents (IPSC) by noradrenaline in rat supraoptic neurons through presynaptic α<inf>2</inf>- adrenoceptors
1998, Brain Research
It has been shown that noradrenergic activation has great influence on the activities of hypothalamic supraoptic neurons. No direct evidence has been reported on the presynaptic effects of adrenoceptors in the actions of noradrenaline on supraoptic neurons, although postsynaptic mechanisms have been studied extensively. In the present study, we explored presynaptic effects of noradrenaline on the supraoptic neurons by measuring spontaneous inhibitory postsynaptic currents (IPSC) with the whole-cell patch-clamp technique. Noradrenaline reduced the frequency of IPSCs in a dose-dependent (10⁻⁹ to 10⁻³ M) and reversible manner. Noradrenaline did not affect the amplitude of IPSCs at concentrations of 10⁻⁹ to 10⁻⁵ M, but reduced the amplitude of IPSCs at high concentrations (10⁻⁴ and 10⁻³ M). The inhibitory effects of noradrenaline were mimicked by the α₂-agonist clonidine (10⁻⁴ M), but not by the α₁-agonist methoxamine (10⁻⁴ M) nor by the β-agonist isoproterenol (10⁻⁴ M). Moreover, the inhibitory effects of noradrenaline on IPSCs were blocked by the non-selective α antagonist phentolamine (10⁻⁴ M) or the selective α₂-antagonist yohimbine (10⁻⁴ M), but not by the α₁-antagonist prazosin (10⁻⁴ M). These results suggest that noradrenaline inhibits release of GABA from the presynaptic GABAergic terminals of the supraoptic neurons by activating presynaptic α₂-adrenoceptors and such presynaptic mechanisms may play a role in the excitatory control of SON neurons by noradrenergic neurons.

View all citing articles on Scopus

View full text

Noradrenergic modulation of γ-aminobutyric acid outflow from the human cerebral cortex

Abstract

Eur. J. Pharmacol.

Brain Res.

Trends Pharmacol. Sci.

Neurosci. Lett.

Neuroscience

J. Biol. Chem.

Trends Pharmacol. Sci.

Brain Res.

Trends Neurosci.

Brain Res.